Pancreatic Cancer Research

ResearcherShiga University of Medical ScienceActive in the last 2 years

Hirochika Toyama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0360-8460; OpenAlex author ID A5028793955. Sources: OpenAlex.

Their work

Papers
54 (first author 13, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
147
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 4 papers · 2019: 3 papers · 2020: 3 papers · 2021: 4 papers · 2022: 7 papers · 2023: 9 papers · 2024: 6 papers · 2025: none · 2026: 12 papers

Papers 50 of 54

  1. Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single-Center Retrospective Study. First author DOI 10.1002/ags3.70100↗
  2. Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial. Co-author DOI 10.1002/jhbp.70117↗
  3. Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis o… Co-author DOI 10.1007/s00535-026-02413-5↗
  4. Proton Radiotherapy with Induction Chemotherapy for Locally Advanced Pancreatic Cancer: A Retrospective Analysis of Treatment Strategy and Outcomes. Co-author DOI 10.1016/j.clon.2026.104204↗
  5. Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase I… Co-author DOI 10.1016/j.ejca.2026.117034↗
  6. Intraoperative frozen section analysis of the portal or superior mesenteric vein transection margin in pancreatectomy with venous resection for pancreatic canc… First author DOI 10.1016/j.gassur.2026.102410↗
  7. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Co-author DOI 10.1097/sla.0000000000006730↗
  8. Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. Co-author DOI 10.1245/s10434-025-18491-3↗
  9. ASO Visual Abstract: Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. Co-author DOI 10.1245/s10434-025-18718-3↗
  10. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  11. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  12. Delayed Initiation of S-1 Adjuvant Chemotherapy Impairs Survival in Patients With Curatively Resected Pancreatic Cancer. First author DOI 10.21873/anticanres.18004↗
  13. Temporal progression of pancreatic cancer computed tomography findings until diagnosis: A large-scale multicenter study. Co-author DOI 10.1002/ueg2.12557↗
  14. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-023-02069-5↗
  15. Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a multicenter retrospective study. Co-author DOI 10.1007/s00535-024-02149-0↗
  16. Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy. First author DOI 10.1016/j.pan.2024.07.012↗
  17. Rim Enhancement on Contrast-Enhanced CT as a Predictor of Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics14080782↗
  18. Treatment and Prognosis for Pancreatic Duct Disruption Associated With Pancreatic Cancer: A Case Series of 15 Patients. Co-author DOI 10.7759/cureus.67482↗
  19. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  20. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancre… First author DOI 10.1002/jhbp.1353↗
  21. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-022-01939-8↗
  22. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal… Co-author DOI 10.1007/s00535-023-02020-8↗
  23. A case of pancreatic ductal adenocarcinoma concomitant with IgG4-related disease in the pancreas and the stomach. Co-author DOI 10.1007/s12328-023-01814-w↗
  24. Clinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.asjsur.2022.03.043↗
  25. Benefits of pancreatic parenchymal endoscopic ultrasonography in predicting microscopic precancerous lesions of pancreatic cancer. Co-author DOI 10.1038/s41598-023-38920-1↗
  26. Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study. Co-author DOI 10.1186/s13014-023-02301-9↗
  27. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Anal… Co-author DOI 10.1245/s10434-023-13569-2↗
  28. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Co-author DOI 10.1002/cnr2.1507↗
  29. Abbreviated Gadoxetic Acid-Enhanced MRI for the Detection of Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/jmri.28059↗
  30. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Co-author DOI 10.1097/sla.0000000000004535↗
  31. Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center… Co-author DOI 10.1186/s13014-022-02001-w↗
  32. Editorial Comment to "High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer:… First author DOI 10.1245/s10434-022-11587-0↗
  33. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1245/s10434-022-11704-z↗
  34. Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0266620↗
  35. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial). Co-author DOI 10.1007/s00280-020-04174-1↗
  36. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer. Co-author DOI 10.1111/cas.14914↗
  37. [A Patient with Ascending Jejunal Mesentery Metastasis of Pancreatic Cancer after a Subtotal Stomach-Preserving Pancreaticoduodenectomy]. First author PMID 35045476↗
  38. [A Case of Pancreatic Cancer with Gastric Wall Recurrence after Laparoscopic Distal Pancreatectomy Due to Needle Tract Seeding following EUS-FNA]. First author PMID 35045477↗
  39. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Co-author DOI 10.1111/cas.14258↗
  40. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy… Co-author DOI 10.1186/s12885-020-07698-0↗
  41. Response to: "timing of administration of indocyanine green for fluorescence-guided surgery in pancreatic cancer: response to Shirakawa et al." First author DOI 10.1186/s12893-020-00815-7↗
  42. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-019-53801-2↗
  43. A prospective single-center protocol for using near-infrared fluorescence imaging with indocyanine green during staging laparoscopy to detect small metastasis … First author DOI 10.1186/s12893-019-0635-0↗
  44. Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07471-z↗
  45. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgica… Co-author DOI 10.1016/j.pan.2017.11.005↗
  46. Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Co-author DOI 10.1016/j.pan.2017.12.007↗
  47. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Co-author DOI 10.1016/j.pan.2018.04.005↗
  48. Pathological and Radiological Splenic Vein Involvement are Predictors of Poor Prognosis and Early Liver Metastasis After Surgery in Patients with Pancreatic Ad… First author DOI 10.1245/s10434-017-6274-8↗
  49. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1097/mpa.0000000000000761↗
  50. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophi… Co-author DOI 10.1007/s00595-015-1206-3↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takumi Fukumoto · 34 shared papers, 2011–2026 · strength 4.66
  2. Yoshihide Nanno · 13 shared papers, 2014–2026 · strength 2.65
  3. Jun Ishida · 14 shared papers, 2014–2026 · strength 2.45
  4. Hiroaki Yanagimoto · 11 shared papers, 2018–2026 · strength 2.09
  5. Atsuhiro Masuda · 15 shared papers, 2017–2024 · strength 1.96
  6. Takuya Mizumoto · 9 shared papers, 2018–2026 · strength 1.95
  7. Sadaki Asari · 14 shared papers, 2011–2026 · strength 1.83
  8. Katsuhiko Uesaka · 11 shared papers, 2019–2026 · strength 1.74
  9. Yuzo Kodama · 12 shared papers, 2021–2024 · strength 1.69
  10. Takashi Kobayashi · 13 shared papers, 2017–2024 · strength 1.61
  11. Keitaro Sofue · 13 shared papers, 2017–2024 · strength 1.53
  12. Arata Sakai · 11 shared papers, 2018–2024 · strength 1.49
  13. Masanori Gonda · 9 shared papers, 2022–2024 · strength 1.26
  14. Kohei Yamakawa · 8 shared papers, 2022–2024 · strength 1.10
  15. Masahiro Tsujimae · 8 shared papers, 2022–2024 · strength 1.09
  16. Dongha Lee · 4 shared papers, 2026 · strength 1.02
  17. Soichiro Morinaga · 8 shared papers, 2019–2026 · strength 1.00
  18. Shohei Abe · 7 shared papers, 2022–2024 · strength 0.94
  19. Takeshi Tanaka · 7 shared papers, 2022–2024 · strength 0.93
  20. Tomoo Itoh · 7 shared papers, 2022–2024 · strength 0.93
  21. Akira Fukutomi · 5 shared papers, 2020–2026 · strength 0.87
  22. Mika Miki · 6 shared papers, 2023–2024 · strength 0.86
  23. Sachiyo Shirakawa · 8 shared papers, 2012–2023 · strength 0.84
  24. Shinichiro Takahashi · 6 shared papers, 2019–2026 · strength 0.82
  25. Ippei Matsumoto · 9 shared papers, 2011–2026 · strength 0.80

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.